NCT03665155View on ClinicalTrials.gov

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

April 20, 2020

Study Completion Date

April 20, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

89Zr-daratumumab

2 mCi of 89Zr-daratumumab will be administered on day 0.

DEVICE

PET/CT scans

PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.

OTHER

Blood draws

Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,

Trial Locations (1)

10065

Memorial Slaon-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | Biotech Hunter | Biotech Hunter